ClinicalTrials.gg
Not yet recruitingNCT06655103Updated Oct 23, 2024

The Effect of the Educational Movie Shown to Pediatric Patients Receiving Intrathecal Chemotherapy Treatment on Pre-Procedure Fear and Post-Procedure Pain in Children

An interventional study of Educational movie in Injections, Spinal, Child, Only and Virtual Reality, sponsored by Ege University. Not yet recruiting at 1 site in Turkey. Open to participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Ege University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
5 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Pain by Ege University — 6 open to participants now, 7 under way, none of them phase 3. Pain · Ege University.

Planned enrollment
16th of 30
99 · median 100
Started
2024
with 3 others
No phase
29 of 31
6 open now
Registered
20th of 31
by date

Among the 31 studies in Pain by Ege University, this one is the 16th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2024, is one of 29 with no phase, and was the 20th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 31 studies in Pain by Ege University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 5 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Pain by Ege University, or all of them as a file.
02

Study summary

In this study, which is planned to be conducted in a randomized controlled experimental design, nonpharmacological methods (educational film shown with virtual reality goggles and cartoon shown with virtual reality goggles) applied to children aged 5-10 years who will receive intrathecal chemotherapy treatment before intrathecal chemotherapy treatment were evaluated. It is aimed to determine the effect on pre-procedure fear and post-procedure pain.

The study is planned to be conducted between November 2024 and November 2025. The population of the study will consist of children between the ages of 5-10 years who receive inpatient treatment in the Pediatric Hematology Clinic of Izmir Ege University Hospital (Health Practice and Research Center). Random sampling method and stratified randomization method will be used for sample selection. In the calculation of the sample size of the study, using G-Power 3.1.9.7 program; type 1 error (α) 0.05, power (1- β) 99% and Cohen's effect size (δ) 0.5, the sample size to represent the main mass was determined as 90 children for this study. However, when the dropout rate is set as 10% for data loss that may occur in the study, the minimum number to be reached for the study is targeted as 99 (intervention group 1 n=33, intervention group 2 n=33, control group n=33).

Research data will be collected after project acceptance. In all three groups, children and their parents will be informed before the study and their written and verbal consent will be obtained. Data will be collected by using the "Introductory Information Form", "Intervention Follow-up Form" and "Child Fear Scale (CFS)", "Wong Baker FACES (WB-FACES) Pain Rating Scale" and "Visual Analog Scale (VAS)" prepared by the researchers with the feedback of nurses, parents and children.

Statistical analyses will be performed using IBM SPSS Statistics 26.0 (IBM SPSS Statistics for Windows) package program. The significance level will be set as 0.05 in all analyzes. In the study, numerical data will be calculated using mean, standard deviation, median, minimum, maximum values and categorical data will be calculated using frequency and ratio values.

With the nonparametric Brunner-Langer model, the before-after change (group effect, before-after effect and interaction effect) of fear scores in the educational film, cartoon and control groups will be examined using R 3.3.1 software (R software, version 3.3.1, package: nparLD, R Foundation for Statistical Computing, Vienna, Austria; http://r-project.org). In order to visually examine this change, the 'relative effects' graph (since the nonparametric method is used) will be utilized.

When the Brunner-Langer model shows that the before-after change in the groups is not similar (interaction \< 0.05), the before-after comparison in each group will be made separately with the Wilcoxon sign test, and the differences between the groups will be compared with the Kruskal-Wallis test by taking the after-before difference. After Kruskal-Wallis, pairwise comparisons will be made with the Dunn test, and then Bonferroni correction will be used for p values. The agreement between the measurements of Nurses, Parents and Children will be evaluated by Intraclass Correlation (ICC) analysis.

03

Conditions studied

  • Injections, Spinal
  • Child, Only
  • Virtual Reality
  • Fear
  • Pain
  • Chemotherapy

Browse trials for

Keywords

  • Intrathecal
  • Child
  • Virtual reality
  • Fear
  • Pain
  • chemotherapy
04

Who can participate

Ages eligible
5 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 5-10 years old
  • Family's acceptance to participate in the research
  • The child's willingness to participate in the research
  • Absence of a pancytopenic period
  • No sensory loss
  • Developed language skills/no communication problems
  • Lack of a psychological diagnosis Cognitive abilities are developed in an age-appropriate manner
  • Having not used any anelgesic drug in the last four hours

Exclusion criteria

Exclusion Criteria:

  • The child has an infection that requires isolation
  • The child wears glasses
  • Child removes virtual reality goggles applied before intrathecal chemotherapy treatment
  • The child does not want to fill in the scales after the application
  • The child or parent wants to leave the study
  • The child has a physical and psychological deficit that prevents him/her from wearing the glasses that will be worn on his/her head in order to watch virtual reality
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    Group shown educational movie with virtual reality glasses

    Measurements will be performed in three stages. In the first measurement; electrodermal activity, pulse, respiration and oxygen (O2) saturation values together with fear and pain scales 30 minutes before IT chemotherapy treatment without any intervention, in the second measurement; Electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales after the application of virtual reality goggles 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).

    Other: Educational movie

  • Experimental
    Group watching cartoons with virtual reality glasses

    Measurements will be performed in three stages. In the first measurement; electrodermal activity, pulse, respiration and oxygen (O2) saturation values together with fear and pain scales 30 minutes before IT chemotherapy treatment without any intervention, in the second measurement; Electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales after the application of virtual reality goggles 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).

    Other: Educational movie

  • No intervention
    The group that received routine clinical care without any intervention

    Measurements will be performed in three stages parallel to the treatment groups. In the first measurement; electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales 30 minutes before IT chemotherapy treatment without any intervention, in the second measurement; In the second measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values together with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).

Interventions

  • OtherEducational movie

    There are three groups in this research. The 1st group will be shown an educational movie about intrathecal chemotherapy treatment before intrathecal chemotherapy treatment, the 2nd group will be shown a cartoon movie before intrathecal chemotherapy treatment, and the 3rd group will not receive any intervention before intrathecal chemotherapy treatment. In all groups, measurements will be made in parallel; fear and pain scales as well as electrodermal activity, pulse, respiration and O2 saturation values 30 minutes before IT chemotherapy treatment, in the second measurement; In the second measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).

    Also known as: Cartoons, Without any intervention

06

What researchers measure

Primary outcomes

  1. Pain

    Wong Baker FACES (WB-FACES) Pain Rating Scale: The WB-FACES scale was first developed by Donna Wong and Connie Baker in 1981 and updated in 1983. This scale is used for pain assessment in children between the ages of 3 and 18. A simple tool including five different facial expressions was created by taking into account the way children express their pain. This scale is used to determine the level of pain in children aged 3-18 years. It contains a total of 6 facial expressions and provides a rating scale between 0-10. It does not require word or numeric values and is reported to be a reliable and valid measurement tool in the evaluation of acute pain. As the score obtained from the scale increases, the severity of pain increases and as the score decreases, the severity decreases.

    Time frame: Measurements will be performed 30 minutes before intrathecal chemotherapy (without any intervention to the child), 15 minutes before intrathecal chemotherapy (after application of virtual reality goggles), and 30-60 minutes after IT chemotherapy (after t

  2. Pain

    Visual Analog Scale (VAS): The Visual Analog Scale (VAS), developed by Price et al. (1983), is one of the widely used tools for pain assessment in children. The VAS is characterized by its ease of use and simple structure. It allows children to mark their pain on a line or a line. The scale consists of a line at one end indicating no pain and a line at the other end indicating excruciating pain. By marking their own pain, children determine how much pain they feel.

    Time frame: Measurements will be performed 30 minutes before intrathecal chemotherapy (without any intervention to the child), 15 minutes before intrathecal chemotherapy (after application of virtual reality goggles), and 30-60 minutes after IT chemotherapy (after t

  3. Fear

    Child Fear Scale: The Facial Expressions of Fear Scale was developed by McKinley et al. (2003) as "The Faces Anxiety Scale" to measure the fear or anxiety of adults hospitalized in the intensive care unit. The Child Fear Scale was developed by McMurty et al. (2011) by adapting the Facial Expressions of Fear Scale to children. The scale consists of five drawn facial expressions ranging from a neutral expression (0=no anxiety) to a frightened face (4=severe anxiety) and can be easily evaluated by researchers and health professionals who provide care/intervention to children. The scale was translated into Turkish by Gerçeker et al. in 2018. Content validity is the most frequently used method in the validity of measurement tools. The content validity index of the CQS was found to be 0.89.

    Time frame: Measurements will be performed 30 minutes before intrathecal chemotherapy (without any intervention to the child), 15 minutes before intrathecal chemotherapy (after application of virtual reality goggles), and 30-60 minutes after IT chemotherapy (after t

Secondary outcomes

  1. Electrodermal activity

    Electrodermal activity device: An electrodermal activity device is a biometric measurement tool that measures changes in electrical conductivity on the skin surface. This device is often used to study a person's emotional and physiological responses. In particular, EDA reflects changes in the skin's conductivity due to the activity of sweat glands, which is associated with states such as stress, fear, excitement or arousal. In this study, the electrodermal activity device will be used simultaneously with the Child Fear Scale to measure the fear experienced by children before, during and after intrathecal chemotherapy treatment.

    Time frame: Measurements will be performed 30 minutes before intrathecal chemotherapy (without any intervention to the child), 15 minutes before intrathecal chemotherapy (after application of virtual reality goggles), and 30-60 minutes after IT chemotherapy (after t

  2. Pulse

    Pulseoximeter Calibrated pulseoximeter device will be used for pulse and O2 saturation measurements of children.

    Time frame: Measurements will be performed 30 minutes before intrathecal chemotherapy (without any intervention to the child), 15 minutes before intrathecal chemotherapy (after application of virtual reality goggles), and 30-60 minutes after IT chemotherapy (after t

  3. Respiration

    Pulseoximeter Calibrated pulseoximeter device will be used for pulse and O2 saturation measurements of children.

    Time frame: Measurements will be performed 30 minutes before intrathecal chemotherapy (without any intervention to the child), 15 minutes before intrathecal chemotherapy (after application of virtual reality goggles), and 30-60 minutes after IT chemotherapy (after t

  4. O2 saturation

    Pulseoximeter Calibrated pulseoximeter device will be used for pulse and O2 saturation measurements of children.

    Time frame: Measurements will be performed 30 minutes before intrathecal chemotherapy (without any intervention to the child), 15 minutes before intrathecal chemotherapy (after application of virtual reality goggles), and 30-60 minutes after IT chemotherapy (after t

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Oct 2025, 11 months later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 11 months is close to that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2024
First posted
Oct 23, 2024
StartEst.
Nov 30, 2024
Primary completionEst.
Oct 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06655103
Lead sponsor
Ege University
Responsible party
Aycin Ezgi ONEL (Principal Investigator, Ege University) — Principal investigator
First posted
Oct 23, 2024
Start date
Nov 30, 2024 (estimated)
Primary completion
Oct 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Oct 23, 2024

Study contacts

Ayçin Ezgi ONEL, Research Assistant
Contact
aycinezgiakaydin@gmail.com
+90 (543)6561920

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion